One of the most promising gene therapy trials to date has been halted because two patients developed mild side effects. Over the past 3 years, the biotech company Avigen of Alameda, California, had been conducting clinical safety tests with a therapy shown to partially cure hemophilia in dogs. But after the latest of seven patients developed minor signs of toxicity, Avigen last week stopped the trial.
No takes yet. Share an insight, caveat, or question.
Jocelyn Kaiser (2004) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: